Differences in Tumor-Infiltrating Lymphocyte Counts in the Peritumoral Area in Patients Undergoing Hepatic Resection After Lenvatinib and Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma

IF 3.1 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2025-04-18 DOI:10.1002/cam4.70445

Katsuya Toshida, Shinji Itoh, Yasushi Tanaka, Takeo Toshima, Shohei Yoshiya, Takuma Izumi, Norifumi Iseda, Yuriko Tsutsui, Yuki Nakayama, Takuma Ishikawa, Mizuki Ninomiya, Takeshi Iwasaki, Yoshinao Oda, Tomoharu Yoshizumi

{"title":"Differences in Tumor-Infiltrating Lymphocyte Counts in the Peritumoral Area in Patients Undergoing Hepatic Resection After Lenvatinib and Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma","authors":"Katsuya Toshida, Shinji Itoh, Yasushi Tanaka, Takeo Toshima, Shohei Yoshiya, Takuma Izumi, Norifumi Iseda, Yuriko Tsutsui, Yuki Nakayama, Takuma Ishikawa, Mizuki Ninomiya, Takeshi Iwasaki, Yoshinao Oda, Tomoharu Yoshizumi","doi":"10.1002/cam4.70445","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>With advances in systemic therapy, the number of patients with hepatocellular carcinoma (HCC) who can undergo hepatic resection has increased in recent years, but there are no reports evaluating the immune status in the peritumoral area.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We enrolled 14 patients who underwent hepatic resection after lenvatinib (LEN, <i>n</i> = 7) or atezolizumab plus bevacizumab (ATZ/BEV, <i>n</i> = 5) therapy. Tumor-infiltrating lymphocytes (TILs), including CD3+ and CD8+ TILs, in the peritumoral area were evaluated by hematoxylin and eosin staining and immunohistochemistry.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The median TIL counts after LEN and ATZ/BEV therapy were 32 and 92 cells/0.237 mm<sup>2</sup>, respectively (<i>p</i> = 0.0044). The median CD3+ TIL counts after LEN and ATZ/BEV therapy were 26 and 71 cells/0.237 mm<sup>2</sup>, respectively (<i>p</i> = 0.0057). The median CD8+ TIL counts after LEN and ATZ/BEV therapy were 14 and 42 cells/0.237 mm<sup>2</sup>, respectively (<i>p</i> = 0.0044).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>TIL counts, including those of CD3+ and CD8+ TILs, in the peritumoral area were significantly higher after ATZ/BEV than after LEN therapy.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 8","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70445","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70445","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

With advances in systemic therapy, the number of patients with hepatocellular carcinoma (HCC) who can undergo hepatic resection has increased in recent years, but there are no reports evaluating the immune status in the peritumoral area.

Methods

We enrolled 14 patients who underwent hepatic resection after lenvatinib (LEN, n = 7) or atezolizumab plus bevacizumab (ATZ/BEV, n = 5) therapy. Tumor-infiltrating lymphocytes (TILs), including CD3+ and CD8+ TILs, in the peritumoral area were evaluated by hematoxylin and eosin staining and immunohistochemistry.

Results

The median TIL counts after LEN and ATZ/BEV therapy were 32 and 92 cells/0.237 mm², respectively (p = 0.0044). The median CD3+ TIL counts after LEN and ATZ/BEV therapy were 26 and 71 cells/0.237 mm², respectively (p = 0.0057). The median CD8+ TIL counts after LEN and ATZ/BEV therapy were 14 and 42 cells/0.237 mm², respectively (p = 0.0044).

Conclusion

TIL counts, including those of CD3+ and CD8+ TILs, in the peritumoral area were significantly higher after ATZ/BEV than after LEN therapy.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肝切除术患者在Lenvatinib和Atezolizumab加贝伐单抗治疗肝癌后肿瘤浸润淋巴细胞计数的差异

目的随着全身治疗的进展，近年来可以行肝切除术的肝细胞癌（HCC）患者数量有所增加，但尚未见评估肿瘤周围免疫状况的报道。方法：我们招募了14例在lenvatinib （LEN, n = 7）或atezolizumab + bevacizumab （ATZ/BEV, n = 5）治疗后行肝切除术的患者。采用苏木精染色、伊红染色及免疫组化检测肿瘤周围的肿瘤浸润淋巴细胞（til），包括CD3+和CD8+ til。结果LEN和ATZ/BEV治疗后的中位TIL计数分别为32和92个细胞/0.237 mm2 （p = 0.0044）。LEN和ATZ/BEV治疗后的中位CD3+ TIL计数分别为26和71个细胞/0.237 mm2 （p = 0.0057）。LEN和ATZ/BEV治疗后的中位CD8+ TIL计数分别为14和42个细胞/0.237 mm2 （p = 0.0044）。结论ATZ/BEV治疗后肿瘤周围TIL计数，包括CD3+和CD8+ TIL计数均明显高于LEN治疗后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.